U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029

October 2022 | 103 pages | ID: U38C8E399DD4EN
Meticulous Market Research Pvt. Ltd.

Abstracts

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers)- Forecast to 2029

The U.S. RWE solutions market is expected to grow at a CAGR of 13.1% from 2022 to 2029 to reach $2.22 billion by 2029

Following a thorough secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities

Growing incidence of chronic & infectious diseases, delays in drug development and the subsequent increase in development costs, rising focus towards personalized healthcare, a shift from volume to value-based care, and rapidly growing big data in healthcare are the key factors driving steady growth in the U.S. RWE solutions market. Further, significant opportunities for existing market players and new entrants are provided by rising focus on end-to-end RWE services, and rising adoption of wearable devices and AI in RWE

Based on component, in 2022, the datasets segment is expected to command the largest share in the market. Real-world data (RWD) are derived from various sources associated with outcomes in a heterogeneous patient population in real-world settings. Datasets are present in a secondary format on which retrospective studies are conducted to generate real-world evidence. This real-world evidence provides meaningful insights into unmet needs and the clinical and economic impacts on patients and healthcare systems. It also determines the outcomes based on much larger data samples, reduces costs, and improves the efficiency of clinical trials.

Based on application, the drug development & approvals segment is expected to show the fastest growth rate in the forecast period. Factors attributing towards the growth of this segment are increasing demand for real-world data and real-world evidence to accelerate drug discovery and development, and increasing investments by biopharmaceutical companies in R&D.

In the field of drug development, quality-of-life metrics, and Patient-Reported Outcome Measures (PROMs) are now becoming common elements in clinical trials. The evidence generated from real-world data is regularly utilized to inform aspects of drug development. The role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs.

Based on end user, the pharmaceutical & medical device companies segment is expected to show the fastest growth rate in the forecast period. The growth of this segment is primarily attributed to the increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

The cost of developing a new drug was more than ~USD 2,600 million in 2020 compared to USD 802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face.

The key companies operating in the U.S. RWE solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA HOLDINGS INC. (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).

Scope of the Report

U.S. RWE Solutions Market, by Component

• Datasets
• Disparate Datasets
• EMR/EHR/Clinical Data
• Claims & Billing Data
• Pharmacy Data
• Product/Disease Registries Data
• Other Disparate Datasets
• Integrated Datasets
• Consulting and Analytics

(Note – Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

U.S. RWE Solutions Market, by Application

• Market Access & Reimbursement/Coverage Decisions
• Drug Development & Approvals
• Oncology
• Neurology
• Immunology
• Cardiovascular Diseases
• Other Therapeutic Areas
• Post Market Surveillance
• Medical Device Development & Approvals
• Clinical and Regulatory Decision-Making

(Note – Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases)

U.S. RWE Solutions Market, by End User

• Pharmaceutical, Biotechnology, and Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Other End Users

(Note – Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

Contents

1. INTRODUCTION

1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency

2. RESEARCH METHODOLOGY

2.1. Research Process
2.2. Data Collection & Validation
  2.2.1. Secondary Research
  2.2.2. Primary Research
2.3. Market Assessment
  2.3.1. Market Size Estimation
    2.3.1.1. Bottom-Up Approach
    2.3.1.2. Top-Down Approach
    2.3.1.3. Growth Forecast
  2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study

3. EXECUTIVE SUMMARY

4. MARKET INSIGHTS

4.1. Market Overview
4.2. Drivers
  4.2.1. Growing Burden of Chronic and Infectious Diseases
  4.2.2. Rising Focus Towards Personalized Healthcare
  4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
  4.2.4. Shift Towards Value-Based Care
  4.2.5. Rapidly Growing Big Data in Healthcare
4.3. Restraints
  4.3.1. Reluctance to Rely on Real-World Studies
4.4. Opportunities
  4.4.1. Rising Focus on End-to-End RWE Services
  4.4.2. Rising Adoption of Wearable Devices and Artificial Intelligence in RWE
4.5. Challenges
  4.5.1. Lack of Standardized Methodologies to Develop RWE
4.6. Key Market Trends
  4.6.1. Growing Adoption of RWE in Drug Development and Commercialization
  4.6.2. Rising Number of Consolidations
  4.6.3. Improved Patient Outcomes and Value Creation from Real-World Evidence
4.7. Impact Assessment of COVID-19 on the U.S. RWE Solutions Market

5. REGULATORY ANALYSIS – U.S. REAL-WORLD EVIDENCE (RWE) SOLUTIONS MARKET

6. PRICING MODELS (EMR/GENOMIC/INTEGRATED DATASETS)

6.1. Introduction
6.2. Pay Per Patient Record (Volume-Based Pricing)
6.3. Pay Per Usage (Value-Based Pricing)
6.4. Annual Subscription

7. U.S. REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT

7.1. Introduction
7.2. Datasets
  7.2.1. Disparate Datasets
    7.2.1.1. EMR/EHR/Clinical Data
    7.2.1.2. Claims & Billing Data
    7.2.1.3. Pharmacy Data
    7.2.1.4. Product/Disease Registries Data
    7.2.1.5. Other Disparate Datasets
  7.2.2. Integrated Datasets
7.3. Consulting & Analytics

8. U.S. REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION

8.1. Introduction
8.2. Market Access & Reimbursement/Coverage Decisions
8.3. Drug Development & Approvals
  8.3.1. Oncology
  8.3.2. Neurology
  8.3.3. Immunology
  8.3.4. Cardiovascular Diseases
  8.3.5. Other Therapeutic Areas
8.4. Medical Device Development & Approvals
8.5. Post-Market Surveillance
8.6. Other Applications

9. U.S. REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER

9.1. Introduction
9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
9.3. Healthcare Payers
9.4. Healthcare Providers
9.5. Other End Users

10. COMPETITIVE LANDSCAPE

10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2020)
  10.4.1. IQVIA Holdings, Inc. (U.S.)
  10.4.2. ICON plc (Ireland)
  10.4.3. PPD, Inc. (U.S.)

11. COMPANY PROFILES (BUSINESS OVERVIEW, FINANCIAL OVERVIEW, SOLUTION PORTFOLIO, STRATEGIC DEVELOPMENTS)

11.1. Anthem, Inc.
11.2. Clinigen Group plc.
11.3. Cognizant Technology Solutions Corporation
11.4. ICON plc
11.5. IQVIA HOLDINGS INC.
11.6. Oracle Corporation
11.7. PAREXEL International Corporation
11.8. PerkinElmer, Inc.
11.9. PPD, Inc.
11.10. SAS Institute Inc.
11.11. UnitedHealth Group Incorporated
11.12. Flatiron Health, Inc.

List Of Tables

LIST OF TABLES

Table 1 U.S. Real-World Evidence Solutions Market Drivers: Impact Analysis (2022-2029)
Table 2 Total Per-Study Cost (In Usd Million), by Phase and Therapeutic Area
Table 3 Sources of Healthcare Data
Table 4 U.S. Real-World Evidence Solutions Market Restraints: Impact Analysis (2022-2029)
Table 5 Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
Table 6 U.S. Real-World Evidence Solutions Market Size, by Component, 2012–2029 (USD Million)
Table 7 U.S. Real-World Evidence Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 8 U.S. RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 9 U.S. Real-World Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 10 U.S. RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 11 Estimated Number of New Cancer Cases in the U.S. (2019–2023)
Table 12 Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
Table 13 Other Therapeutic Areas: Drugs in the R&D Pipeline
Table 14 U.S. RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 15 Recent Developments, by Company, 2018–2022

List Of Figures

LIST OF FIGURES

Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 U.S. Real-World Evidence Solutions Market, by Component, 2022 Vs. 2029 (USD Million)
Figure 9 U.S. Real-World Evidence Solutions Market, by Application, 2022 Vs. 2029 (USD Million)
Figure 10 U.S. Real-World Evidence Solutions Market, by End User, 2022 Vs. 2029 (USD Million)
Figure 11 Market Dynamics
Figure 12 Number of People in the U.S. With Chronic Conditions (2000–2030)
Figure 13 Percentage of Personalized Medicines Approved (2015-2020)
Figure 14 U.S. Real-World Evidence Solutions Market Size, by Component, 2022–2029 (USD Million)
Figure 15 U.S.: Number of E-Prescriptions, 2013–2020 (Billions)
Figure 16 U.S. Real-World Evidence Solutions Market Size, by Application, 2022–2029 (USD Million)
Figure 17 Dalys of Neurological Disorders in the U.S., 2010–2021 (In Thousands)
Figure 18 U.S.: Hepatitis A Virus (HAV) Infections, 2013–2020
Figure 19 U.S. Real-World Evidence Solutions Market Size, by End User, 2022–2029 (USD Million)
Figure 20 U.S. Pharmaceutical R&D Spending, 1980–2019 (USD Billion)
Figure 21 Key Growth Strategies Adopted by Leading Players (2018–2022)
Figure 22 U.S. Real-World Evidence Solutions: Competitive Benchmarking
Figure 23 Market Share Analysis: U.S. Real-World Evidence Solutions Industry (2021)
Figure 24 Anthem, Inc.: Financial Overview (2021)
Figure 25 Clinigen Group plc: Financial Overview (2021)
Figure 26 Cognizant Technology Solutions Corporation: Financial Overview (2021)
Figure 27 ICON plc: Financial Overview (2021)
Figure 28 IQVIA HOLDINGS INC.: Financial Overview (2021)
Figure 29 Oracle Corporation: Financial Overview (2021)
Figure 30 PerkinElmer, Inc.: Financial Overview (2022)
Figure 31 PPD, Inc.: Financial Overview (2020)
Figure 32 SAS Institute Inc.: Financial Overview (2021)
Figure 33 UnitedHealth Group Incorporated.: Financial Overview (2021)